On August 3, 2021, Black Diamond Therapeutics, Inc. appointed Karsten Witt, M.D., the company’s Senior Vice President of Clinical Development, Interim Chief Medical Officer until a permanent successor is appointed. Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August 4, 2021. On August 3, 2021, the company also appointed Elizabeth Buck, Ph.D., the Company’s Co-Founder and Executive Vice President, Discovery & Translational Sciences, Chief Scientific Officer. Effective August 11, 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief Scientific Officer, who notified the Company on July 12, 2021 of his resignation from the Company to assume the role of chief executive officer at another company. Dr. Roberts will serve as an advisor to the Company following his departure.